MedTrace Logo

Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma

NCT01765231 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2017-01-10

No results posted yet for this study

Summary

The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma.

Conditions

Interventions

DRUG

Entecavir prophylaxis

Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy

DRUG

Observation arm

Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Jun Zhu · Peking University Cancer Hospital & Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01765231 on ClinicalTrials.gov